Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Lung Cancer

  Free Subscription


Articles published in Oncologist

Retrieve available abstracts of 137 articles:
HTML format



Single Articles


    October 2024
  1. ARRIETA O, Ramos-Ramirez M, Garces-Flores H, Cabrera-Miranda LA, et al
    Evaluation of a risk-sharing agreement for atezolizumab treatment in patients with non-small cell lung cancer: a strategy to improve access in low-income countries.
    Oncologist. 2024 Oct 19:oyae272. doi: 10.1093.
    PubMed     Abstract available


  2. CAVAGNA RO, Escremim de Paula F, Berardinelli GN, Bonatelli M, et al
    Molecular profile of driver genes in lung adenocarcinomas of Brazilian patients who have never smoked: implications for targeted therapies.
    Oncologist. 2024;29:e1419-e1424.
    PubMed     Abstract available


    September 2024
  3. SHAW J, Pundole X, Balasubramanian A, Anderson ES, et al
    Recent treatment patterns and real-world survival following first-line anti-PD-L1 treatment for extensive-stage small cell lung cancer.
    Oncologist. 2024 Sep 30:oyae234. doi: 10.1093.
    PubMed     Abstract available


  4. APTER L, Sharman Moser S, Gazit S, Chodick G, et al
    Healthcare resource utilization and associated cost in patients with metastatic non-small cell lung cancer treated in the immunotherapy era.
    Oncologist. 2024 Sep 28:oyae240. doi: 10.1093.
    PubMed     Abstract available


  5. SEBASTIAN NT, Stokes WA, Behera M, Jiang R, et al
    The association of azole antifungals with overall survival in patients with non-small cell lung cancer receiving immune checkpoint inhibitors.
    Oncologist. 2024 Sep 25:oyae262. doi: 10.1093.
    PubMed     Abstract available



  6. Correction to: Homeopathic Treatment as an Add-On Therapy May Improve Quality of Life and Prolong Survival in Patients with Non-Small Cell Lung Cancer: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Three-Arm, Multicenter Study.
    Oncologist. 2024 Sep 24:oyae253. doi: 10.1093.
    PubMed    


  7. ALVES DE SOUZA G, Dornellas DMS, Campregher PV, Teixeira CHA, et al
    Complete response to capmatinib in a patient with metastatic lung adenocarcinoma harboring CD47-MET fusion: a case report.
    Oncologist. 2024;29:764-767.
    PubMed     Abstract available


  8. FLOREZ N, Patel SP, Wakelee H, Bazhenova L, et al
    Proceedings of the 1st biannual bridging the gaps in lung cancer conference.
    Oncologist. 2024 Sep 5:oyae228. doi: 10.1093.
    PubMed     Abstract available


    August 2024
  9. DHAWALE TM, Bhat RS, Johnson PC, Srikonda S, et al
    Telemedicine-based serious illness conversations, healthcare utilization, and end of life care among patients with advanced lung cancer.
    Oncologist. 2024 Aug 29:oyae216. doi: 10.1093.
    PubMed     Abstract available


  10. BOULANGER MC, Schneider JL, Lin JJ
    Advances and future directions in ROS1 fusion-positive lung cancer.
    Oncologist. 2024 Aug 23:oyae205. doi: 10.1093.
    PubMed     Abstract available


  11. MACK PC, Keller-Evans RB, Li G, Lofgren KT, et al
    Real-World Clinical Performance of a DNA-Based Comprehensive Genomic Profiling Assay for Detecting Targetable Fusions in Nonsquamous NSCLC.
    Oncologist. 2024;29:e984-e996.
    PubMed     Abstract available


    July 2024
  12. FALADE A, Zubiri L, Wu CY, Perlman K, et al
    Immune-related adverse events requiring hospitalization in patients with lung cancer: implications and insights.
    Oncologist. 2024 Jul 26:oyae189. doi: 10.1093.
    PubMed     Abstract available


  13. MEYER ML, Hirsch FR, Bunn PA, Ujhazy P, et al
    Calls to action on lung cancer management and research.
    Oncologist. 2024 Jul 13:oyae169. doi: 10.1093.
    PubMed     Abstract available


  14. MEHTA GU, Vellanki PJ, Ren Y, Amatya AK, et al
    FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutations.
    Oncologist. 2024 Jul 6:oyae151. doi: 10.1093.
    PubMed     Abstract available


  15. CHANG AEB, Piper-Vallillo AJ, Mak RH, Lanuti M, et al
    The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC.
    Oncologist. 2024;29:609-618.
    PubMed     Abstract available


  16. CHENG W, Xu T, Yang L, Yan N, et al
    Dramatic response to crizotinib through MET phosphorylation inhibition in rare TFG-MET fusion advanced squamous cell lung cancer.
    Oncologist. 2024 Jul 2:oyae166. doi: 10.1093.
    PubMed     Abstract available


    June 2024
  17. JAYAKRISHNAN R, Kwiatkowski DJ, Rose MG, Nassar AH, et al
    Topography of mutational signatures in non-small cell lung cancer: emerging concepts, clinical applications, and limitations.
    Oncologist. 2024 Jun 22:oyae091. doi: 10.1093.
    PubMed     Abstract available


  18. NEAL JW, Minichiello K, Brennick R, Huang RSP, et al
    A process to reanalyze clinical DNA sequencing data for biomarker matching in the Lung-MAP Master Protocol.
    Oncologist. 2024;29:e843-e847.
    PubMed     Abstract available


    May 2024
  19. VALLEJO J, Singh H, Larkins E, Drezner N, et al
    Impact of Increasing PD-L1 Levels on Outcomes to PD-1/PD-L1 Inhibition in Patients With NSCLC: A Pooled Analysis of 11 Prospective Clinical Trials.
    Oncologist. 2024;29:422-430.
    PubMed     Abstract available


    April 2024
  20. CHEN HW, Kuo YW, Chen CY, Chang CH, et al
    Increased Tuberculosis Reactivation Risk in Patients Receiving Immune Checkpoint Inhibitor-Based Therapy.
    Oncologist. 2024;29:e498-e506.
    PubMed     Abstract available


  21. ARRIOLA E, Jaal J, Edvardsen A, Silvoniemi M, et al
    Feasibility and User Experience of Digital Patient Monitoring for Real-World Patients With Lung or Breast Cancer.
    Oncologist. 2024;29:e561-e569.
    PubMed     Abstract available


  22. ALLENDE S, Turcott JG, Verastegui E, Rodriguez-Mayoral O, et al
    Early Incorporation to Palliative Care (EPC) in Patients With Advanced Non-Small Cell Lung Cancer: The PACO Randomized Clinical Trial.
    Oncologist. 2024 Apr 1:oyae050. doi: 10.1093.
    PubMed     Abstract available


    March 2024
  23. XU Y, Ji H, Zhang Y, Xiong L, et al
    Combination of EGFR-TKI and Chemotherapy Versus EGFR-TKI Monotherapy as Neoadjuvant Treatment of Stage III-N2 EGFR-Mutant Non-Small Cell Lung Cancer.
    Oncologist. 2024 Mar 25:oyae052. doi: 10.1093.
    PubMed     Abstract available


  24. PASELLO G, Lorenzi M, Scattolin D, Del Conte A, et al
    Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World.
    Oncologist. 2024 Mar 23:oyae043. doi: 10.1093.
    PubMed     Abstract available


  25. XU Y, Wen N, Haddad RI, Sonis ST, et al
    Comparisons of Non-Oral Immune-Related Adverse Events Among Patients With Cancer With Different Oral Toxicity Profiles.
    Oncologist. 2024;29:e382-e391.
    PubMed     Abstract available


    February 2024
  26. STRICKER T, Jain N, Ma E, Yu E, et al
    Clinical Value of Timely Targeted Therapy for Patients With Advanced Non-Small Cell Lung Cancer With Actionable Driver Oncogenes.
    Oncologist. 2024 Feb 28:oyae022. doi: 10.1093.
    PubMed     Abstract available


  27. BRIA E, Morgillo F, Garassino MC, Ciardiello F, et al
    Atezolizumab Plus Carboplatin and Etoposide in Patients with Untreated Extensive-Stage Small-Cell Lung Cancer: Interim Results of the MAURIS Phase IIIb Trial.
    Oncologist. 2024 Feb 20:oyad342. doi: 10.1093.
    PubMed     Abstract available


    January 2024
  28. KATAYAMA Y, Yamada T, Sawada R, Kawachi H, et al
    Prospective Observational Study of Ramucirumab Plus Docetaxel After Combined Chemoimmunotherapy in Patients With Non-Small-Cell Lung Cancer.
    Oncologist. 2024 Jan 18:oyae001. doi: 10.1093.
    PubMed     Abstract available


  29. GERBER DE, Wang Y, Ramalingam SS, Bhalla S, et al
    Incidence, Correlates, and Prognostic Significance of Mixed Response in Advanced Non-small Cell Lung Cancer.
    Oncologist. 2024 Jan 11:oyad335. doi: 10.1093.
    PubMed     Abstract available


  30. WANG H, Fan Z, Yang X, Wu Q, et al
    Sequential Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Induced Radical Surgery in Oligometastatic Non-small Cell Lung Cancer: A Case Report.
    Oncologist. 2024 Jan 10:oyad339. doi: 10.1093.
    PubMed     Abstract available


  31. BONANNO L, Lorenzi M, Massa D, De Nuzzo M, et al
    Immune-Related Diarrhea and Colitis in Non-small Cell Lung Cancers: Impact of Multidisciplinary Management in a Real-World Setting.
    Oncologist. 2024;29:e118-e130.
    PubMed     Abstract available


  32. HORIUCHI K, Ikemura S, Sato T, Shimozaki K, et al
    Pre-existing Interstitial Lung Abnormalities and Immune Checkpoint Inhibitor-Related Pneumonitis in Solid Tumors: A Retrospective Analysis.
    Oncologist. 2024;29:e108-e117.
    PubMed     Abstract available


  33. JORDAN J, Maki RG
    The Weighted Toxicity Score: Confirmation of a Simple Metric to Communicate Toxicity in Randomized Trials of Systemic Cancer Therapy.
    Oncologist. 2024;29:67-74.
    PubMed     Abstract available


    November 2023

  34. Correction to: Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer.
    Oncologist. 2023 Nov 24:oyad316. doi: 10.1093.
    PubMed    


  35. STRICKLER JH, Yoshino T, Stevinson K, Eichinger CS, et al
    Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review.
    Oncologist. 2023;28:e981-e994.
    PubMed     Abstract available


    October 2023
  36. HU X, Melson JW, Pan SS, Salei YV, et al
    Screening, Diagnosis, and Initial Care of Asian and White Patients With Lung Cancer.
    Oncologist. 2023 Oct 5:oyad272. doi: 10.1093.
    PubMed     Abstract available


  37. SILVERSTEIN J, Wright F, Wang M, Young A, et al
    Evaluating Survival After Hospitalization Due to Immune-Related Adverse Events From Checkpoint Inhibitors.
    Oncologist. 2023;28:e950-e959.
    PubMed     Abstract available


    September 2023
  38. SHANG X, Zhang C, Kong R, Zhao C, et al
    Construction of a Diagnostic Model for Small Cell Lung Cancer Combining Metabolomics and Integrated Machine Learning.
    Oncologist. 2023 Sep 14:oyad261. doi: 10.1093.
    PubMed     Abstract available


  39. HASEGAWA T, Okuyama T, Uemura T, Matsuda Y, et al
    Elements of End-of-Life Discussions Associated With Patients' Reported Outcomes and Actual End-of-Life Care in Patients With Pretreated Lung Cancer.
    Oncologist. 2023 Sep 5:oyad245. doi: 10.1093.
    PubMed     Abstract available


    August 2023
  40. ELKRIEF A, Riccuiti B, Alessi JV, Fei T, et al
    Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer.
    Oncologist. 2023 Aug 17:oyad197. doi: 10.1093.
    PubMed     Abstract available


  41. GENTZLER RD, Villaruz LC, Rhee JC, Horton B, et al
    Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399.
    Oncologist. 2023 Aug 9:oyad221. doi: 10.1093.
    PubMed     Abstract available


  42. HUNT AL, Nutcharoen A, Randall J, Papazian A, et al
    Integration of Multi-omic Data in a Molecular Tumor Board Reveals EGFR-Associated ALK-Inhibitor Resistance in a Patient With Inflammatory Myofibroblastic Cancer.
    Oncologist. 2023;28:730-736.
    PubMed     Abstract available


  43. FARHA N, Faisal MS, Allende DS, Sleiman J, et al
    Characteristics of Immune Checkpoint Inhibitor-Associated Gastritis: Report from a Major Tertiary Care Center.
    Oncologist. 2023;28:706-713.
    PubMed     Abstract available


    July 2023
  44. SULLIVAN HW, O'Donoghue AC, Boudewyns V, Paquin RS, et al
    Patient Understanding of Oncology Clinical Trial Endpoints in Direct-to-Consumer Television Advertising.
    Oncologist. 2023;28:e542-e553.
    PubMed     Abstract available


  45. WEI Y, Zheng L, Yang X, Luo Y, et al
    Identification of Immune Subtypes and Candidate mRNA Vaccine Antigens in Small Cell Lung Cancer.
    Oncologist. 2023 Jul 3:oyad193. doi: 10.1093.
    PubMed     Abstract available


    June 2023
  46. GENTZLER RD, Mohindra NA, Jalal SI, Reckamp KL, et al
    Phase I/II Trial of Carboplatin, Nab-paclitaxel, and Pembrolizumab for Advanced Non-Small Cell Lung Cancer: Hoosier Cancer Research Network LUN13-175.
    Oncologist. 2023 Jun 30:oyad180. doi: 10.1093.
    PubMed     Abstract available


  47. DUBE-PELLETIER M, Labbe C, Cote J, Pelletier-St-Pierre AA, et al
    Pembrolizumab Every 6 Weeks Versus Every 3 Weeks in Advanced Non-Small Cell Lung Cancer.
    Oncologist. 2023 Jun 26:oyad182. doi: 10.1093.
    PubMed     Abstract available


  48. SMYTH EN, John J, Tiu RV, Willard MD, et al
    Clinicogenomic factors and treatment patterns among patients with advanced non-small cell lung cancer with or without brain metastases in the United States.
    Oncologist. 2023 Jun 26:oyad170. doi: 10.1093.
    PubMed     Abstract available


  49. JOHN AO, Ramnath N
    Neoadjuvant Versus Adjuvant Systemic Therapy for Early-Stage Non-Small Cell Lung Cancer: The Changing Landscape Due to Immunotherapy.
    Oncologist. 2023 Jun 20:oyad125. doi: 10.1093.
    PubMed     Abstract available


  50. MOORE AM, Nooruddin Z, Reveles KR, Koeller JM, et al
    Health Equity in Patients Receiving Durvalumab for Unresectable Stage III Non-Small Cell Lung Cancer in the US Veterans Health Administration.
    Oncologist. 2023 Jun 19:oyad172. doi: 10.1093.
    PubMed     Abstract available


  51. BAIJAL S, Crosbie P, Fenemore J, Desai K, et al
    Variations in Genomic Testing in Non-small Cell Lung Carcinoma: A Healthcare Professional Survey of Current Practices in the UK.
    Oncologist. 2023 Jun 13:oyad134. doi: 10.1093.
    PubMed     Abstract available


  52. PRUIS MA, Krebs MG, Plummer R, De Vos F, et al
    A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung Cancer.
    Oncologist. 2023 Jun 1:oyad146. doi: 10.1093.
    PubMed     Abstract available


    May 2023
  53. ALTAN M, Soto F, Zhong LL, Akhmedzhanov FO, et al
    Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center Experience.
    Oncologist. 2023 May 8:oyad118. doi: 10.1093.
    PubMed     Abstract available


  54. STENZINGER A, Cuffel B, Paracha N, Vail E, et al
    Supporting Biomarker-Driven Therapies in Oncology: A Genomic Testing Cost Calculator.
    Oncologist. 2023;28:e242-e253.
    PubMed     Abstract available


  55. MATHIAS K, Rouhani S, Olson D, Bass AR, et al
    Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events.
    Oncologist. 2023;28:440-448.
    PubMed     Abstract available


  56. JOHNSON ML, Patel MR, Aljumaily R, Jones SF, et al
    A Phase Ib Dose-Escalation Study of LCL161 Plus Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies.
    Oncologist. 2023 May 2:oyad029. doi: 10.1093.
    PubMed     Abstract available


    April 2023
  57. WANG C, Zhao K, Hu S, Dong W, et al
    Clinical Outcomes of Afatinib Versus Osimertinib in Patients With Non-Small Cell Lung Cancer With Uncommon EGFR Mutations: A Pooled Analysis.
    Oncologist. 2023 Apr 28:oyad111. doi: 10.1093.
    PubMed     Abstract available


  58. AGGARWAL C, Maity AP, Bauml JM, Long Q, et al
    A Phase II Open-Label Trial of Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS-Mutant Non-Small Cell Lung Cancer.
    Oncologist. 2023 Apr 26:oyad106. doi: 10.1093.
    PubMed     Abstract available


  59. TANIMURA K, Uchino J, Kimura H, Hiranuma O, et al
    Ramucirumab Plus Docetaxel for Patients with Non-small cell Lung Cancer with Brain Metastases: A Multicenter, Open-Label Single-Arm Phase II Trial.
    Oncologist. 2023 Apr 13:oyad013. doi: 10.1093.
    PubMed     Abstract available


  60. HERZBERG BO, Manji GA
    KRAS: Druggable at Last.
    Oncologist. 2023;28:283-286.
    PubMed     Abstract available


  61. DANZIGER N, Sokol ES, Graf RP, Hiemenz MC, et al
    Variable Landscape of PD-L1 Expression in Breast Carcinoma as Detected by the DAKO 22C3 Immunohistochemistry Assay.
    Oncologist. 2023;28:319-326.
    PubMed     Abstract available


  62. ICHT O, Leader A, Batat E, Yosef L, et al
    Arterial and Venous Thromboembolism in ALK-Rearrangement-Positive Non-small Cell Lung Cancer: A Population-Based Cohort Study.
    Oncologist. 2023 Apr 4:oyad061. doi: 10.1093.
    PubMed     Abstract available


    March 2023
  63. CHEN Y, Yu J, Meng X
    Postoperative Radiotherapy in Completely Resected IIIA-N2 Non-small Cell Lung Cancer: Quit or Not?
    Oncologist. 2023 Mar 18:oyad066. doi: 10.1093.
    PubMed    


  64. LI LX, Cappuzzo F, Matos I, Socinski MA, et al
    Low Risk of Hyperprogression with First-Line Chemoimmunotherapy for Advanced Non-Small Cell Lung Cancer: Pooled Analysis of 7 Clinical Trials.
    Oncologist. 2023 Mar 11:oyad043. doi: 10.1093.
    PubMed     Abstract available


  65. ZHANG J, Johnson M, Barve M, Bazhenova L, et al
    Practical Guidance for the Management of Adverse Events in Patients with KRASG12C-Mutated Non-Small Cell Lung Cancer Receiving Adagrasib.
    Oncologist. 2023 Mar 9:oyad051. doi: 10.1093.
    PubMed     Abstract available


    February 2023
  66. NOVELLO S, Califano R, Reinmuth N, Tamma A, et al
    RET Fusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment Landscape.
    Oncologist. 2023 Feb 23:oyac264. doi: 10.1093.
    PubMed     Abstract available



  67. Correction to: Management of Lung Cancer in the Patient with Interstitial Lung Disease.
    Oncologist. 2023 Feb 9:oyad018. doi: 10.1093.
    PubMed    


    December 2022
  68. BARLESI F, Isambert N, Felip E, Cho BC, et al
    Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-beta and PD-L1, in Patients With Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors.
    Oncologist. 2022 Dec 26:oyac253. doi: 10.1093.
    PubMed     Abstract available


  69. WOODFORD K, Koo K, Reynolds J, Stirling RG, et al
    Persisting Gaps in Optimal Care of Stage III Non-small Cell Lung Cancer: An Australian Patterns of Care Analysis.
    Oncologist. 2022 Dec 20:oyac246. doi: 10.1093.
    PubMed     Abstract available


    November 2022
  70. FRANK AJ, Dagogo-Jack I, Dobre IA, Tait S, et al
    Management of Lung Cancer in the Patient with Interstitial Lung Disease.
    Oncologist. 2022 Nov 25:oyac226. doi: 10.1093.
    PubMed     Abstract available


  71. CHIHARA Y, Takeda T, Goto Y, Nakamura Y, et al
    A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study.
    Oncologist. 2022;27:903-e834.
    PubMed     Abstract available


  72. YAO J, Bergsland E, Aggarwal R, Aparicio A, et al
    DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms.
    Oncologist. 2022;27:940-951.
    PubMed     Abstract available


    October 2022

  73. Expression of Concern: Homeopathic Treatment as an Add-On Therapy May Improve Quality of Life and Prolong Survival in Patients with Non-Small Cell Lung Cancer: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Three-Arm, Multicenter Study.
    Oncologist. 2022 Oct 31. pii: 6782256. doi: 10.1093.
    PubMed    


  74. MOHAMED L, Manjrekar S, Ng DP, Walsh A, et al
    The Effect of Biomarker Use on the Speed and Duration of Clinical Trials for Cancer Drugs.
    Oncologist. 2022;27:849-856.
    PubMed     Abstract available


    September 2022
  75. ALVES PINTO I, de Oliveira Cavagna R, Virginio da Silva AL, Dias JM, et al
    EGFR Mutations and PD-L1 Expression in Early-Stage Non-Small Cell Lung Cancer: A Real-World Data From a Single Center in Brazil.
    Oncologist. 2022 Sep 13. pii: 6696863. doi: 10.1093.
    PubMed     Abstract available


  76. HASEGAWA T, Okuyama T, Uemura T, Matsuda Y, et al
    Prognostic Awareness and Discussions of Incurability in Patients with Pretreated Non-Small Cell Lung Cancer and Caregivers: A Prospective Cohort Study.
    Oncologist. 2022 Sep 6. pii: 6693237. doi: 10.1093.
    PubMed     Abstract available


  77. FUJIWARA Y, Takahashi Y, Okada M, Kishimoto T, et al
    Phase I Study of Tremelimumab Monotherapy or in Combination With Durvalumab in Japanese Patients With Advanced Solid Tumors or Malignant Mesothelioma.
    Oncologist. 2022;27:e703-e722.
    PubMed     Abstract available


    August 2022
  78. HSU ML, Murray JC, Psoter KJ, Zhang J, et al
    Clinical Features, Survival, and Burden of Toxicities in Survivors More Than One Year After Lung Cancer Immunotherapy.
    Oncologist. 2022 Aug 16. pii: 6668266. doi: 10.1093.
    PubMed     Abstract available



  79. Correction to: Multicenter Real-World Study on Effectiveness and Early Discontinuation Predictors in Patients With Non-small Cell Lung Cancer Receiving Nivolumab.
    Oncologist. 2022 Aug 6. pii: 6657714. doi: 10.1093.
    PubMed    


  80. OFFIN M, Rusch VW, Rimner A, Adusumilli PS, et al
    Evolving Landscape of Initial Treatments for Patients with Malignant Pleural Mesotheliomas: Clinical Trials to Clinical Practice.
    Oncologist. 2022;27:610-614.
    PubMed    


    July 2022
  81. SAKURADA T, Nokihara H, Koga T, Zamami Y, et al
    Prevention of Pemetrexed-Induced Rash Using Low-Dose Corticosteroids: A Phase II Study.
    Oncologist. 2022;27:e554-e560.
    PubMed     Abstract available


  82. WANG J, Martin-Romano P, Cassier P, Johnson M, et al
    Phase I Study of JNJ-74699157 in Patients with Advanced Solid Tumors Harboring the KRAS G12C Mutation.
    Oncologist. 2022;27:536-e553.
    PubMed     Abstract available


  83. JAHANZEB M, Lin HM, Wu Y, Zhang P, et al
    Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States.
    Oncologist. 2022 Jul 4. pii: 6628677. doi: 10.1093.
    PubMed     Abstract available


    June 2022
  84. IKEDA S, Kato T, Kenmotsu H, Ogura T, et al
    Atezolizumab for Pretreated Non-Small Cell Lung Cancer with Idiopathic Interstitial Pneumonia: Final Analysis of Phase II AMBITIOUS Study.
    Oncologist. 2022 Jun 27. pii: 6618634. doi: 10.1093.
    PubMed     Abstract available


  85. MACK PC, Klein MI, Ayers KL, Zhou X, et al
    Targeted Next-Generation Sequencing Reveals Exceptionally High Rates of Molecular Driver Mutations in Never-Smokers With Lung Adenocarcinoma.
    Oncologist. 2022;27:476-486.
    PubMed     Abstract available


  86. GANTZER J, Davidson G, Vokshi B, Weingertner N, et al
    Immune-Desert Tumor Microenvironment in Thoracic SMARCA4-Deficient Undifferentiated Tumors with Limited Efficacy of Immune Checkpoint Inhibitors.
    Oncologist. 2022;27:501-511.
    PubMed     Abstract available


    May 2022
  87. HUANG RSP, Harries L, Decker B, Hiemenz MC, et al
    Clinicopathologic and Genomic Landscape of Non-Small Cell Lung Cancer Brain Metastases.
    Oncologist. 2022 May 22. pii: 6590419. doi: 10.1093.
    PubMed     Abstract available


  88. MURUGESAN K, Jin DX, Comment LA, Fabrizio D, et al
    Association of CD274 (PD-L1) Copy Number Changes with Immune Checkpoint Inhibitor Clinical Benefit in Non-Squamous Non-Small Cell Lung Cancer.
    Oncologist. 2022 May 22. pii: 6590420. doi: 10.1093.
    PubMed     Abstract available


  89. ISAWA T, Toi Y, Sugawara S, Taguri M, et al
    Incidence, Clinical Characteristics, and Predictors of Cardiovascular Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors.
    Oncologist. 2022;27:e410-e419.
    PubMed     Abstract available


    April 2022
  90. PASELLO G, Lorenzi M, Calvetti L, Oliani C, et al
    Multicenter Real-World Study on Effectiveness and Early Discontinuation Predictors in Patients With Non-small Cell Lung Cancer Receiving Nivolumab.
    Oncologist. 2022 Apr 16. pii: 6569250. doi: 10.1093.
    PubMed     Abstract available


  91. POPAT S, Hsia TC, Hung JY, Jung HA, et al
    Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG).
    Oncologist. 2022;27:255-265.
    PubMed     Abstract available


    March 2022
  92. LEMMON CA, Zabor EC, Pennell NA
    Modeling the Cost-Effectiveness of Adjuvant Osimertinib for Patients with Resected EGFR-mutant Non-Small Cell Lung Cancer.
    Oncologist. 2022 Mar 14. pii: 6548144. doi: 10.1093.
    PubMed     Abstract available


  93. JIAN H, Wang K, Cheng Y, Ding L, et al
    Phase I Trial of a Third Generation EGFR Mutant-Selective Inhibitor (D-0316) in Patients with Advanced Non-Small Cell Lung Cancer.
    Oncologist. 2022;27:163-e213.
    PubMed     Abstract available


  94. TAN R, Yun C, Seetasith A, Sheinson D, et al
    Impact of Immune Checkpoint Inhibitors on COVID-19 Severity in Patients with Cancer.
    Oncologist. 2022;27:236-243.
    PubMed     Abstract available


  95. WELLS JC, Sidhu A, Ding K, Smoragiewicz M, et al
    Complementary Medicine Use Amongst Patients with Metastatic Cancer Enrolled in Phase III Clinical Trials.
    Oncologist. 2022;27:e286-e293.
    PubMed     Abstract available


  96. STURGILL EG, Misch A, Jones CC, Luckett D, et al
    Discordance in Tumor Mutation Burden from Blood and Tissue Affects Association with Response to Immune Checkpoint Inhibition in Real-World Settings.
    Oncologist. 2022;27:175-182.
    PubMed     Abstract available


  97. LORENZI M, Ferro A, Cecere F, Scattolin D, et al
    First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study.
    Oncologist. 2022;27:87-e115.
    PubMed     Abstract available


  98. PENG W, Cao L, Chen L, Lin G, et al
    Comprehensive Characterization of the Genomic Landscape in Chinese Pulmonary Neuroendocrine Tumors Reveals Prognostic and Therapeutic Markers (CSWOG-1901).
    Oncologist. 2022;27:e116-e125.
    PubMed     Abstract available


  99. PAVAN A, Ferro A, Fortarezza F, Schiavon M, et al
    Tumor Immune-Infiltrate Landscape After Chemo-Radiotherapy in a Case Series of Patients with Non-small Cell Lung Cancer: Pretreatment Predictors and Correlation With Outcome.
    Oncologist. 2022;27:e199-e202.
    PubMed     Abstract available


    February 2022
  100. MORABITO A, Manzo A, Montanino A, Rachiglio AM, et al
    Liquid Biopsy Testing for the Management of Patient with Non-Small Cell Lung Cancer Carrying a Rare Exon-20 EGFR Insertion.
    Oncologist. 2022;27:7-12.
    PubMed     Abstract available


  101. MOSKOVITZ M, Dudnik E, Shamai S, Rotenberg Y, et al
    ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data.
    Oncologist. 2022;27:e76-e84.
    PubMed     Abstract available


  102. MIKKELSEN MK, Lund CM, Vinther A, Tolver A, et al
    Effects of a 12-Week Multimodal Exercise Intervention Among Older Patients with Advanced Cancer: Results from a Randomized Controlled Trial.
    Oncologist. 2022;27:67-78.
    PubMed     Abstract available


    December 2021
  103. LI J, Wang Q, Ge J, Tian Y, et al
    BRAF V600E Mediates Crizotinib Resistance and Responds to Dabrafenib and Trametinib in a ROS1-Rearranged Non-Small Cell Lung Cancer: A Case Report.
    Oncologist. 2021;26:e2115-e2119.
    PubMed     Abstract available


  104. ARRIETA O, Lara-Mejia L, Bautista-GonzAlez E, Heredia D, et al
    Clinical Impact of the COVID-19 Pandemic in Mexican Patients with Thoracic Malignancies.
    Oncologist. 2021;26:1035-1043.
    PubMed     Abstract available


  105. OZA AM, Dubois F, Hegg R, Hernandez CA, et al
    A Long-Term Extension Study of Bevacizumab in Patients With Solid Tumors.
    Oncologist. 2021;26:e2254-e2264.
    PubMed     Abstract available


    November 2021
  106. PETRILLO LA, Zhou AZ, Sullivan R, Volandes A, et al
    Knowledge About Risks, Benefits, and Curative Potential of Immunotherapy Among Patients with Advanced Cancer.
    Oncologist. 2021;26:e2090-e2093.
    PubMed     Abstract available


  107. AMELOT A
    Regarding "Surgical Metastasectomy in the Spine: A Review Article".
    Oncologist. 2021;26:e2097.
    PubMed    


  108. ZHANG G, Xia P, Zhao S, Yuan L, et al
    Gefitinib Combined with Cetuximab for the Treatment of Lung Adenocarcinoma Harboring the EGFR-Intergenic Region (SEC61G) Fusion and EGFR Amplification.
    Oncologist. 2021;26:e1898-e1902.
    PubMed     Abstract available


    October 2021
  109. OSPINA AV, Bruges R, Mantilla W, Triana I, et al
    Impact of COVID-19 Infection on Patients with Cancer: Experience in a Latin American Country: The ACHOCC-19 Study.
    Oncologist. 2021;26:e1761-e1773.
    PubMed     Abstract available


  110. CHEN X, Sheikh K, Nakajima E, Lin CT, et al
    Radiation Versus Immune Checkpoint Inhibitor Associated Pneumonitis: Distinct Radiologic Morphologies.
    Oncologist. 2021;26:e1822-e1832.
    PubMed     Abstract available


  111. GAN HK, Millward M, Jalving M, Garrido-Laguna I, et al
    A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3 Monoclonal Antibody, in HER3-Expressing Solid Tumors.
    Oncologist. 2021;26:e1844-e1853.
    PubMed     Abstract available


    September 2021
  112. MINCHOM A, Tan AC, Massarelli E, Subbiah V, et al
    Patient-Reported Outcomes with Selpercatinib Among Patients with RET Fusion-Positive Non-small Cell Lung Cancer in the Phase 1/2 LIBRETTO-001 Trial.
    Oncologist. 2021 Sep 15. doi: 10.1002/onco.13976.
    PubMed     Abstract available


  113. ARAI D, Sato T, Nakachi I, Fujisawa D, et al
    Longitudinal Assessment of Prognostic Understanding in Advanced Lung Cancer Patients and Its Association with Their Psychological Distress.
    Oncologist. 2021 Sep 12. doi: 10.1002/onco.13973.
    PubMed     Abstract available


  114. GOSSLING GCL, Chedid MF, Pereira FS, da Silva RK, et al
    Outcomes and Prognostic Factors of Patients with Metastatic Colorectal Cancer Who Underwent Pulmonary Metastasectomy with Curative Intent: A Brazilian Experience.
    Oncologist. 2021;26:e1581-e1588.
    PubMed     Abstract available


    August 2021
  115. LIN S, Luo S, Gu D, Li M, et al
    First-line durvalumab in addition to etoposide and platinum for extensive-stage small cell lung cancer: a United States-based cost-effectiveness analysis.
    Oncologist. 2021 Aug 25. doi: 10.1002/onco.13954.
    PubMed     Abstract available


  116. LORENZI M, Ferro A, Cecere F, Scattolin D, et al
    First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study.
    Oncologist. 2021 Aug 23. doi: 10.1002/onco.13951.
    PubMed     Abstract available


  117. XIANG M, Yang X, Ren S, Du F, et al
    Anlotinib Combined with S-1 in Third- or Later-Line Stage IV Non-Small Cell Lung Cancer Treatment: A Phase II Clinical Trial.
    Oncologist. 2021 Aug 22. doi: 10.1002/onco.13950.
    PubMed     Abstract available


    July 2021
  118. IVANOVIC M, Knez L, Herzog A, Kovacevic M, et al
    Immunotherapy for metastatic non-small cell lung cancer: Real-world data from an academic Central and Eastern European centre.
    Oncologist. 2021 Jul 19. doi: 10.1002/onco.13909.
    PubMed     Abstract available


  119. LEE Y, Cho Y, Park EY, Park SY, et al
    One-step polymerase chain reaction-free nanowire-based plasma cell-free DNA assay to detect EML4-ALK fusion and to monitor resistance in lung cancer.
    Oncologist. 2021 Jul 17. doi: 10.1002/onco.13902.
    PubMed     Abstract available


  120. TJONG MC, Doherty M, Tan H, Chan WC, et al
    Province-Wide Analysis of Patient Reported Outcomes for Stage IV Non-Small Cell Lung Cancer.
    Oncologist. 2021 Jul 3. doi: 10.1002/onco.13890.
    PubMed     Abstract available


  121. GRAY J, Thompson JC, Carpenter EL, Elkhouly E, et al
    Plasma cell-free DNA genotyping-from an emerging concept to a standard-of-care tool in metastatic non-small cell lung cancer.
    Oncologist. 2021 Jul 3. doi: 10.1002/onco.13889.
    PubMed     Abstract available


  122. GEORGE S, Bell EJ, Zheng Y, Kim R, et al
    The Impact of Adverse Events on Health Care Resource Utilization, Costs, and Mortality Among Patients Treated with Immune Checkpoint Inhibitors.
    Oncologist. 2021;26:e1205-e1215.
    PubMed     Abstract available


  123. AYERS KL, Mullaney T, Zhou X, Liu JJ, et al
    Analysis of Real-World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death-1 and Programmed Cell Death-Ligand 1 Inhibitors in Advanced Non-Small Cell Lung Cancers.
    Oncologist. 2021;26:e1226-e1239.
    PubMed     Abstract available


    June 2021
  124. LOI M, Alifano M, Scorsetti M, Nuyttens JJ, et al
    Judging a Fish by Its Ability to Climb a Tree? A Call for Novel Endpoints in the Appraisal of Ablative Local Treatments of Oligometastatic Cancer.
    Oncologist. 2021;26:e1085-e1086.
    PubMed    


  125. VARLOTTO JM, Sun Z, Ky B, Upshaw J, et al
    A Review of Immunotherapy for Stage III and Metastatic Non-Small Cell Lung Cancer and the Rationale for the ECOG-ACRIN EA5181 Study.
    Oncologist. 2021;26:523-532.
    PubMed     Abstract available


    May 2021
  126. ALKREKSHI A, Tamaskar I
    Safety of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis C Virus Infection.
    Oncologist. 2021;26:e827-e830.
    PubMed     Abstract available


  127. MIYAGAWA C, Takaya H, Sakai K, Nishio K, et al
    A Novel Malignant Peritoneal Mesothelioma with STRN Exon 2 and ALK Exon 20: A Case Report and Literature Review.
    Oncologist. 2021;26:356-361.
    PubMed     Abstract available


    April 2021
  128. KRUG K, Bossert J, Deis N, Krisam J, et al
    Effects of an interprofessional communication approach on support needs, quality of life and mood of advanced lung cancer patients: a randomized trial.
    Oncologist. 2021 Apr 16. doi: 10.1002/onco.13790.
    PubMed     Abstract available


  129. PERAVALI M, Ahn J, Chen K, Rao S, et al
    Safety and Efficacy of First-Line Pembrolizumab in Black Patients with Metastatic Non-Small-Cell Lung Cancer.
    Oncologist. 2021 Apr 12. doi: 10.1002/onco.13787.
    PubMed     Abstract available


  130. BERNICKER EH, Xiao Y, Abraham A, Yang B, et al
    Adherence to NCCN ALK testing guidelines for patients with advanced non-small cell lung cancer in US Community Medical Centers.
    Oncologist. 2021 Apr 6. doi: 10.1002/onco.13779.
    PubMed     Abstract available


  131. JELINEK MJ, Aggarwal C
    Adjuvant Osimertinib: A New Standard of Care.
    Oncologist. 2021;26:263-265.
    PubMed    


  132. VAN BRUMMELEN EMJ, Huijberts S, van Herpen C, Desar I, et al
    Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer.
    Oncologist. 2021;26:290-e545.
    PubMed     Abstract available


  133. JIAO XD, Liu K, Xu M, Yu G, et al
    Metastatic Low-Grade Sarcoma with CARS-ALK Fusion Dramatically Responded to Multiple ALK Tyrosine Kinase Inhibitors: A Case Report with Comprehensive Genomic Analysis.
    Oncologist. 2021;26:e524-e529.
    PubMed     Abstract available


    March 2021
  134. ROSS JS, Sokol ES, Moch H, Mileshkin L, et al
    Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design.
    Oncologist. 2021;26:e394-e402.
    PubMed     Abstract available


  135. WANG Y, Chen Z, Han X, Li J, et al
    Acquired MET D1228N Mutations Mediate Crizotinib Resistance in Lung Adenocarcinoma with ROS1 Fusion: A Case Report.
    Oncologist. 2021;26:178-181.
    PubMed     Abstract available


    January 2021
  136. DURBIN SM, Zubiri L, Niemierko A, Bardia A, et al
    Clinical Outcomes of Patients with Metastatic Cancer Receiving Immune Checkpoint Inhibitors in the Inpatient Setting.
    Oncologist. 2021;26:49-55.
    PubMed     Abstract available


  137. CADRANEL J, Liu SV, Duruisseaux M, Branden E, et al
    Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series.
    Oncologist. 2021;26:7-16.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.